Amneal Pharmaceuticals
AMRX
199 hedge funds and large institutions have $999M invested in Amneal Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 42 funds opening new positions, 84 increasing their positions, 41 reducing their positions, and 22 closing their positions.
156% more call options, than puts
Call options by funds: $3.08M | Put options by funds: $1.2M
105% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 41
91% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 22
9% more funds holding
Funds holding: 182 → 199 (+17)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5.08% less ownership
Funds ownership: 45.78% → 40.7% (-5.1%)
15% less capital invested
Capital invested by funds: $1.18B → $999M (-$180M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$8.35M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$4.59M |
| 3 |
Millennium Management
New York
|
+$4.25M |
| 4 |
BCP
BlackBarn Capital Partners
New York
|
+$3.68M |
| 5 |
Mariner
Overland Park,
Kansas
|
+$3.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$169M |
| 2 |
FI
Fosun International
Hong Kong,
China
|
-$14.3M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$8.7M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$4.43M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$3.73M |
AMRX Hedge Fund Activity: Q4 2024 in Review
199 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q4 2024, worth a combined $999M — down 15% from $1.18B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new AMRX positions and 22 closed out — a net gain of 20 holders — while 84 added to existing stakes and 41 trimmed.
The largest buyer was Nantahala Capital Management, adding an estimated $8.35M. The largest seller was UBS Group, cutting an estimated $169M.
- 199 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q4 2024, up from 182 in Q3 2024.
- Funds reported $999M of Amneal Pharmaceuticals stock for Q4 2024, down 15% quarter-over-quarter.
- 42 funds opened new Amneal Pharmaceuticals positions in Q4 2024 and 22 closed out, a net change of +20 holders.
- The largest Amneal Pharmaceuticals buyer in Q4 2024 was Nantahala Capital Management, an estimated $8.35M added.
- The largest Amneal Pharmaceuticals seller in Q4 2024 was UBS Group, an estimated $169M sold.
Based on aggregated 13F filings for Q4 2024.